Antibodies and peptides in cancer therapy

Jayant J. Khandare, Tamara Minko

Research output: Contribution to journalReview articlepeer-review

36 Scopus citations


Antibodies and peptides play a variety of roles in cancer therapy: monoclonal antibodies (mAbs) and peptides are directly used in anticancer therapy and also as targeting moieties. More than 10 mAbs, either unconjugated or in immunoconjugate forms have been approved for use in oncology. Various peptides, tumor necrosis factors (TNFs), and cell surface-targeted peptides have been identified using phage-display libraries. In combination with standard chemotherapeutic agents, mAbs and peptides can significantly increase the toxicity of anticancer drugs to tumors and reduce their adverse side effects on normal tissues. The present review summarizes some major applications of antibodies and peptides in cancer therapy.

Original languageEnglish (US)
Pages (from-to)401-435
Number of pages35
JournalCritical Reviews in Therapeutic Drug Carrier Systems
Issue number5
StatePublished - 2006

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Pharmaceutical Science


  • Antibodies
  • Cancer
  • Chemotherapy
  • Drug delivery
  • Peptides
  • Tumor targeting


Dive into the research topics of 'Antibodies and peptides in cancer therapy'. Together they form a unique fingerprint.

Cite this